SCHEMBL4287568

SCHEMBL4287568

CC1CC(=O)C2=C(C1)Nc1ccccc1NC2c1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 4/20 0.49
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
GAA P10253 3/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294097 0.82 MEN1 (0.77) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL13704157 0.80 MEN1 (0.50) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL13602828 0.78 KDM4E (0.61) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL4300465 0.77 MEN1 (0.53) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4300454 0.76 HTT (0.43) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL8258897 0.74 ALDH1A1 (0.49) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL4297363 0.73 MEN1 (0.80) MEN1KMT2AMAPTL3MBTL1ALDH1A1
SCHEMBL14582955 0.72 MEN1 (0.75) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL4297351 0.71 MEN1 (0.62) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL14583075 0.71 MEN1 (0.53) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS BONFANTI JEAN-FRANCOIS 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221559-A1 BENZODIAZEPINES AS HCV INHIBITORS GABRA5, GABRA4, GABRA3 MEN1 4829/4885KMT2A 1440/4885LMNA 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.